A big pharma company wanted to foster change in payer attitudes to increase the acceptance of patient-reported outcomes (PROs) and of endpoints beyond overall survival in reimbursement decision-making for oncology drugs.

L.E.K.’s approach

L.E.K. Consulting conducted extensive secondary and primary research, including a market research focus group, to articulate the value story for non-overall survival endpoints and PROs. We also sought to understand the key concerns preventing greater use of these endpoints/PROs in health technology assessments (HTAs).

Value delivered to the client

We provided materials to the client to support its ongoing internal and external engagement strategy as well as a cross-stakeholder action plan to execute (see Figure 1).

L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2024 L.E.K. Consulting LLC

Medtech Policy Support in Japan
scientist behind Japanese flag
See how L.E.K. Consulting helped one client develop their position on the future of pricing and reimbursement for medical devices in Japan.

Related Insights